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Abstract 
 
This paper examines the spatial pattern of the pharmaceutical industry in Ireland and 
in particular the drivers accounting for spatial concentration in the industry.1 Spatial 
concentration indexes indicate a particularly high level of spatial concentration in one 
of the industry’s sub-sectors, namely, drug substance production. This high level of 
concentration has been attributed to the operation of agglomeration advantages, 
notably localisation economies. Based on interview data and secondary sources, a 
detailed investigation of the spatial dynamics and location factors involved suggests 
that these advantages have played, at most, a relatively limited role and that the 
concentration of the industry in and near the two particular urban centres in question 
has largely been driven by government intervention, notably environmental and 
regional planning policy and the related spatially selective provision of well-serviced 
industrial sites and infrastructure.  
 
 
INTRODUCTION 
 
The tendency of economic activity in general, and industrial activity in particular, to 
concentrate in particular localities or regions has long attracted the attention of 
economists and geographers. The debate about the forms and determinants of such 
spatial concentration has recently been reignited (see Martin, 1999; McCann 1995; 
Parr, 2002; Phelps and Ozawa, 2003). Important subjects of this debate include the 
extent to which observed concentrations are driven by agglomeration factors and the 
respective roles of the various agglomerations factors. 
 
Evidence from the literature shows that agglomeration advantages, including 
technological spillovers, are an important driver behind many instances of industrial 
spatial concentration. At the same time, one should also allow for the possibility that, 
in certain situations, agglomeration advantages may play only a limited role in the 
industrial concentration process (see McCann, 1995; Malmberg et al., 2000). In 
certain contexts, an explanation of observed spatial concentration requires that we 
rescue some of the insights of early location theory, notably those related to the role 
of location factors and state intervention in the process of spatial concentration. 
 
The proposition of this paper is that, in certain geographical/sectoral contexts, 
government intervention (notably in the form of spatial/regional planning policy), 
rather than agglomeration advantages, constitutes the most important driver behind 
local/regional industrial concentration. The agglomeration economies at play are 
limited or mainly take the form of urbanisation economies, notably those related to a 
local pool of labour. As is argued below, such concentrations are most likely to occur 
in the following contexts: countries whose governments take a relatively active role in 
regional planning and the related planning of industrial sites; late developing 
countries with limited research and development and innovation activity; and 
                                                 
1 I am deeply indebted to Dr. Proinnsias Breathnach, Professor Ash Amin and Professor Jamie Peck for 
their comments on earlier drafts of this paper. I would also like to thank the participants of the EUNIP 
2006 conference for their helpful suggestions. This research was funded by the Irish Research Council 
for the Humanities and Social Sciences (IRCHSS). 
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industrial sectors characterised by large-scale manufacturing plants that require 
extensive and well-serviced industrial sites.  
 
This proposition will be supported via a study of the spatial dynamics of the 
pharmaceutical industry in Ireland. Nearly all employment in the industry is 
concentrated in foreign-owned manufacturing plants, which have been attracted to 
Ireland primarily by the low rate of corporation tax (currently 12.5%). As such, 
corporation tax has been the primary factor driving the concentration of such plants in 
Ireland at a national level. The focus of this paper, however, is on spatial 
concentration at the local/regional scale. 
 
Existing studies of spatial clusters in the pharmaceutical industry in core economies 
such as the USA, the United Kingdom, Germany and Switzerland generally show or 
suggest that localisation economies, notably technological spillovers, have played an 
important role in the process of spatial concentration (e.g. Gray and Parker, 1998; 
Boasson and MacPherson, 2001; Schreuder 1998; see also Cooke (2003) in relation to 
the growing biopharmaceutical/biotechnology sub-sector). Technological spillover 
advantages arguably pertain more to the R&D and innovation functions than to the 
manufacturing activities in those concentrations. While spatial clustering is also a 
distinctive feature of the Irish pharmaceutical industry, such R&D/innovation 
functions are largely absent in the Irish case.  The purpose of this paper is to analyse 
the locational patterns portrayed by the pharmaceutical industry in Ireland and the key 
influences underlying the observed patterns.  This analysis demonstrates how, in the 
Irish case, very different factors have been driving the process of spatial concentration 
compared with those which operate in the core industrial economies.  
 
The paper begins with a theoretical discussion of the concepts of spatial concentration 
and agglomeration. This is followed by an outline of the development of the 
pharmaceutical industry in Ireland since its inception in the 1950s, separating out the 
various sub-sectors that make up the industry. The next section is methodological, 
focusing, firstly, on data issues encountered in the research and, secondly, on the 
spatial concentration measures utilised in the analysis. The paper then proceeds with a 
description of the spatial distribution of the industry, focusing on two of its main sub-
sectors. It will be shown that the overall level of spatial concentration of the industry 
is entirely due to the spatial concentration of one of the sub-sectors – the manufacture 
of drug substances. The paper continues with a more detailed investigation of the 
spatial dynamics of the drug substance sub-sector, distinguishing between two 
periods: before and after the mid-1980s. The paper ends with some concluding 
comments. 
 
 
THE CONCEPTS OF CONCENTRATION AND AGGLOMERATION 
Marshall (1890) is generally credited for laying the foundations for much of the 
current theorizing about the advantages of industrial spatial concentration. However, 
arguably it was Weber (1909) that developed the first real theory of spatial 
concentration as part of his broader theory of the location of industries. He showed 
how industrial concentration is driven by two forces: the operation of general location 
factors, such as labour costs and transport costs, and additional advantages derived 
from the concentration of firms at one place - agglomeration factors, These 
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agglomeration advantages basically rested on the concept of external economies of 
scale, developed by Marshall. 
 
Weber’s ideas were subsequently developed and refined by neoclassical location 
theorists, notably those contributing to geography’s quantitative revolution of the 
1950s and 1960s. The period since the second half of the 1980s has been 
characterised by a renewed interest in spatial concentration and agglomeration 
involving an increasingly diverse range of theoretical perspectives, including standard 
agglomeration theory, transaction costs, flexible specialisation, innovative milieux 
and institutional and evolutionary economics (Benneworth and Henry, 2004). This 
variety of approaches instigated an intense debate regarding the forms and 
determinants of spatial concentration and the operative processes involved (see Phelps 
and Ozawa, 2003; Parr, 2002; McCann 1995; Martin, 1999; Cumbers and McKinnon, 
2004). Two important foci of this debate have related to: 
 
(1) The specific agglomeration factors that are responsible for particular observed 
concentrations 
(2) The extent to which agglomeration economies are responsible for observed 
spatial concentrations of industrial activity. 
 
A discussion of the first of these foci benefits from an overview of the range of 
possible agglomeration advantages. Marshall’s original contributions are still useful 
for grouping the agglomeration advantages identified in recent literature. His 
observations on the subject of agglomeration2(Marshall, 1890; 1919; 1930) tend to be 
summarised into a triad of external economies – a pooled market for workers with 
specialised skills, a growing number of increasingly specialised input suppliers and 
technological spillovers.  
 
The local pool of labour can provide an efficiency gain for both workers and firms by 
maximising job-matching opportunities and thus reducing search costs (Gordon and 
McCann, 2000). As regards input relations, a localised industry can support more 
suppliers, which increases the level of specialisation and efficiency of the supply base, 
which, in turn, presents an efficiency gain for the customers (Harrison, 1992). The 
actual driver for geographical proximity between firms is the desire to reduce the 
costs of transactions across space (Krugman, 1991). This may involve 
transport/logistics costs and/or the cost of intentional information exchange between 
the two firms (van Egeraat and Jacobson, 2005 and 2006). 
 
The third advantage that is commonly distilled from Marshall’s work, technological 
spillovers, involves informational or knowledge externalities which result from the 
concentration of (both vertically and horizontally) related firms, facilitating processes 
of learning and innovation in the locality (Malmberg and Maskell, 1997 and 2002). 
Technological spillovers are believed to be intensified by proximity in “untraded 
interdependencies” (Storper, 1995) and independent of the degree of intentional 
interaction. Knowledge tends to become embedded in the local milieu (Malmberg, 
1996) – “the mysteries of trade (…) are in the air” (Marshall, 1898, p.350). 
Unintentional interaction (Oerlemans and Meeus, 2005) within a group of firms 
involves the acts of observation and comparison by firms (Malmberg and Maskell, 
                                                 
2 Marshall applied the term localisation. 
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2002) which are facilitated by non-geographical forms of proximity, notably social, 
cultural and institutional proximity (although these other forms of proximity can 
indirectly be augmented by geographical proximity) (Boschma, 2005). 
 
Hoover (1937) made an important contribution to the theory of agglomeration 
economies by dividing such economies into two distinct types: localisation and 
urbanisation economies. Localisation economies, as identified by Marshall (1890), are 
advantages that firms in a single industry (or set of closely related industries) gain 
from being located in the same location while urbanisation economies are advantages 
gained by all firms, regardless of sector, from being located together. Urbanisation 
economies are partially based on economies of scope. They can be regarded as a more 
general form of the localisation economies discussed above. For example, instead of a 
pooled market for workers with specialised skills, in the case of urbanisation 
economies all firms benefit from a pooled market for workers in general. In reality, it 
is not always easy to distinguish between localisation or urbanisation economies, 
which is partly dependent on the level of sectoral aggregation applied (McCann, 
1995; Parr 2002; Glasmeier, 2000; Phelps, 1991). 
 
One of the main criticisms of agglomeration theory is its ineffectiveness in explaining 
or predicting the empirical reality of industrial concentrations (Malmberg and 
Maskell, 2002). It is often unclear which particular agglomeration factors are 
responsible for observed concentrations. Emphasising cost-reduction in inter-firm 
transactions is no longer regarded as being helpful given the fact that in many cases of 
agglomeration most firms have few local backward linkages (Phelps, 1991; McCann, 
1995). Partly as a result of this, the focus of analysis has shifted to technological 
spillovers and related social, cultural and institutional issues (Martin, 1999; Malmberg 
and Maskell, 2002). The problem is that such technological spillovers are difficult to 
identify and measure. In the absence of cost-reduction factors, spatial concentrations 
are often assumed to be shaped by hypothetical local spillovers (McCann, 1995; 
Malmberg and Maskell, 2002) For an example in the context of the Irish 
pharmaceutical industry, see Krugman (1997). However, technological spillovers as 
defined in this paper are unlikely to play a significant role in some industrial 
concentrations, for example concentrations of manufacturing plants with limited 
involvement in innovation and research & development. In the absence of inter-firm 
transactions, the efficiency gains related to the pool of labour may well be the only 
significant agglomeration advantage operative in such concentrations. 
 
In addition, the search for an explanation of agglomerations of a single industry or 
clusters of closely related industries tends to focus on localisation economies rather 
than urbanisation economies. However, many of such single industry agglomerations 
tend to occur in large urban areas such as San Francisco, Los Angeles and London, 
and it has been suggested that at least some single industry agglomerations may 
reflect general urbanisation economies available in such urban areas, rather than 
localisation economies (Simmie, 2004, Gordon and McCann, 2000). These 
advantages may take the forms of efficiency gains due to a pooled market for workers 
and a varied set of input and service suppliers, benefiting a whole range of sectors 
operating in the urban economy. 
 
The second, related, debate concerns the extent to which agglomeration economies 
are responsible for observed spatial concentrations. The literature provides evidence 
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for the fact that agglomeration economies are an important driver behind many 
instances of industrial concentration. At the same time, one should not loose sight of 
the possibility that in certain industrial concentrations agglomeration economies only 
play a limited role (see also McCann, 1995; Malmberg et al., 2000). 
 
In this regard, it is helpful to reintroduce some of the insights of location theory. 
Traditional location theory already showed that operation of general location factors, 
such as labour costs and transport costs, can lead firms to concentrate at material sites, 
transshipment points, cheap labour locations and major markets in order to exploit the 
comparative advantage offered by these points (Dicken and Lloyd, 1990). McCann 
(1995) also makes the point that industrial concentration may be driven by location-
specific factor efficiency costs, without the operation of agglomeration economies. 
Firms can for example be attracted to a particular area due to the prior presence of a 
large pool of skilled or unskilled unemployed workers there. Where the existing factor 
efficiency is not caused by the existing level of concentration, one should not explain 
this concentration in terms of agglomeration economies.  
 
In a similar vein as Weber, Marshall distinguished between causes and advantages of 
localisation (Marshall, 1898). The causes are basically the initial trigger or reason for 
the development of an industry at a particular locality. The advantages are what we 
can interpret as the actual localisation economies that lead to the further expansion of 
the concentration. Marshall identified various causes for the initial concentration of 
industry, including physical conditions and the demand related to the ‘patronage of 
court’. 
 
Important causes for concentration today are related to government intervention. 
Environmental regulation, industrial policies, spatial planning and related spending by 
state and local government authorities/agencies can greatly influence firms in their 
choice for a location and in some cases directly lead to industrial concentration. Some 
of these factors are mediated through government’s role in the supply-side of the 
market for industrial sites, which, along with the locational preferences of 
manufacturing firms, partly determines the pattern of industrial location (Van de 
Krabben and Boekema, 1994; Louw et al. 2004; Lambooy et al. 1997). This role can 
take the form of promoting the development of well-serviced industrial sites at certain 
locations (e.g. through financial/fiscal incentives or the direct provision of well-
serviced industrial sites) and/or that of blocking industrial activities from other 
locations (physical planning and environmental regulations). In some cases such 
government intervention can lead to a concentration of industrial sites in a limited 
number of locations and thus be a very important cause for industrial concentration. 
 
In some cases such industrial concentration may give rise to agglomeration 
advantages that instigate a process of further concentration. However, in certain cases 
agglomeration advantages may remain very limited and, rather than merely 
constituting the initial trigger for a concentration, government intervention remains 
the most important driver for further industrial concentration. 
 
There are probably not many industrial concentrations where agglomeration 
economies are totally absent (Parr, 2002). Notably, most industrial concentrations in 
the vicinity of urban areas are bound to benefit from at least some level of 
urbanisation economies in the form of educational institutions, labour market pooling 
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and infrastructure. However, these may have little impact on the process of spatial 
concentration or only act as ‘reinforcing agglomeration economies’ (Parr, 2003). This 
refers to situations where agglomeration economies are at work, but the concentration 
is not dependent on these agglomeration economies. In many cases therefore, the real 
question is not whether agglomeration economies are present or operative, but rather 
concerns the relative strength of agglomeration economies and whether they are an 
important factor in (further) industrial concentration.  
 
In relation to urbanisation economies it is also important to consider that they may not 
be responsible for driving spatial concentration in particular localities. This is 
because a range of urbanisation economies (although not all) is available in all urban 
centres of a similar size. Therefore, although urbanisation economies may be 
responsible for the concentration of industry in urban centres, they do not always 
serve as an explanation for the concentration in particular urban centres. 
 
The proposition in this article is that, in certain geographical/sectoral contexts, 
government intervention and general location factors, rather than agglomeration 
economies, remain the most important driver behind observed industrial 
concentrations. The agglomeration economies at play are limited and/or mainly take 
the form of urbanisation economies, notably those related to a local pool of labour.  
 
Such concentrations are most likely to occur in sectors that are characterised by large-
scale manufacturing plants requiring large and well-serviced industrial sites with high 
utility requirements. In addition, certain country-specific characteristics may be 
influential. First, different countries have different traditions with respect to the role 
of governments in spatial and industrial planning (Lambooy et al.) and countries 
where governments take a relatively active role in industrial and regional planning are 
more likely to develop such instances of industrial concentration. In such countries, 
industrial and regional policies and the actions of government agencies can have a 
great impact on the spatial distribution of industry, leading to what might be called 
‘government-led’ spatial concentration as opposed to market-driven agglomeration. 
Secondly, the branch-plant type industrial structure of some late-developing countries 
means that many industrial sectors are characterised by limited innovation and R&D 
activity. Technological spillovers are unlikely to play a significant role in industrial 
agglomeration where this is the case. 
 
The pharmaceutical industry in Ireland provides a case where all these conditions 
operate simultaneously. As part of its attempt to catch up with the industrialised world 
after independence was achieved in 1922, the Irish Government has had an active 
involvement in industrial development and regional economic planning. Since the 
1960s industrial development has relied strongly on inward foreign direct investment 
which provided the government with some leverage over the location decisions of 
companies. One of the sub-sectors of the pharmaceutical industry is a prime example 
of a sector characterised by large-scale manufacturing plants, high infrastructural and 
utility requirements and increasingly strict environmental regulations.  
 
 
THE HISTORY OF THE PHARMACEUTICAL INDUSTRY IN IRELAND 
The pharmaceutical industry includes a range of related sub-sectors including finished 
drug products, drug substances, other (non-drug substance) intermediate inputs and 
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diagnostics. Drug substances, also referred to as active pharmaceutical ingredients 
(APIs), are the most important ingredients of a drug product, being responsible for its 
pharmacological effect. They can be manufactured by chemical synthesis, extraction, 
cell culture/fermentation or by recovery from natural sources. (A detailed definition of 
the pharmaceutical industry and the demarcation of its boundaries is provided by 
[Author] (2006)). 
 
Until the 1960s there was virtually no pharmaceutical industry in Ireland (Galvin, 
1998). The post-independence autarkic economic development policies, including the 
Control of Manufacturers Act (designed to keep the ownership of industry in native 
hands), offered little incentive for foreign companies to invest in Ireland (White, 
2000b), while the manufacturing of most pharmaceutical products was too 
sophisticated and required too much capital for indigenous players.  The increasing 
shift towards more outward-looking economic policies (focused strongly on the 
stimulation of exports through the attraction of inward investment) from the end of 
the 1950s (O’Malley, 1989) led quickly to the first substantial investments by foreign 
companies. These companies were primarily attracted by the zero rate of corporation 
tax on profits derived from exports As such, the low corporation tax rate has been the 
primary factor driving the concentration of plants in Ireland at the national level. 
 
The pharmaceutical industry in Ireland really took off in the 1970s. In 1970 the 
Industrial Development Authority (IDA), the state agency responsible for attracting 
inward investment, adopted a focused strategy of searching out emerging growth 
sectors and targeting potential foreign investors via an aggressive direct marketing 
approach (White, 2000a). The fine chemicals industry (including pharmaceuticals) 
was identified as one of the target sectors (Childs, 1996). The IDA succeeded in 
attracting a substantial number of foreign (notably US) companies in the sector, 
employment in which grew strongly, from just over 1,300 in 1972 to 4,750 in 1979 
(see Figure 1). Most growth was accounted for by the drug substance and drug 
product sub-sectors. Very few companies focused on the production of other 
intermediates, with only two employing over 50 staff in 1979 – a situation that would 
change little in subsequent periods. [Insert figure 1 about here] 
 
After a brief period of stagnation during the recessionary early 1980s, pharmaceutical 
manufacturing employment grew continuously from about 4,500 in 1985 to nearly 
19,500 in 2003, by which time pharmaceuticals had become one of Ireland’s leading 
industrial sectors. By far the strongest growth occurred in drug products, although the 
drug substance sub-sector experienced strong growth also, particularly in the second 
half of the 1990s. The growth in drug products manufacturing has been related to the 
increasing harmonisation of regulatory regimes and reduction of other non-tariff 
barriers against international trade in pharmaceutical products (Irish Times, July 2, 
2004). One sub-sector that has experienced strong growth since the second half of the 
1990s is diagnostics. The growth of employment in the pharmaceutical industry has 
involved both expansions of existing companies and the arrival of new companies. 
  
Indigenous companies have played a relatively insignificant role in the sector’s 
growth. During the 1960s there was only a handful of indigenous companies which 
were mainly involved in the formulation of over-the-counter (OTC) drug products. 
Since then, there has been a number of indigenous start-ups, most of them engaged in 
the formulation of veterinary pharmaceuticals or OTC human drug products. More 
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recently, a small number of companies also began manufacturing diagnostic products. 
Nevertheless, in 2003 foreign companies accounted for 93 per cent of total 
pharmaceuticals employment and virtually all employment in the drug substance sub-
sector. Indigenous operations remained relatively small with only seven indigenous 
companies employing more than 50 staff (see Table 1). [Insert Table 1 about here] 
 
DATA AND METHODOLOGY 
The analysis of spatial concentration and its drivers is based on both qualitative and 
quantitative research exercises. The qualitative research involved semi-structured, 
face-to-face, interviews with senior staff at twelve major pharmaceutical plants in the 
period 2005-2006.3 Part of these interviews dealt with the decision-making involved 
in selecting the plants’ locations and the relevance of various agglomeration factors in 
the decision-making process. In addition to the company interviews, the research 
included 12 interviews with current and retired staff at relevant institutions, notably 
the Industrial Development Agency, Cork County Council (within whose boundaries 
one of the main concentrations of pharmaceuticals plants is located) and the 
Environmental Protection Agency. The qualitative micro-level data and contextual 
information derived from these interviews was used to make logical deductions 
regarding the relevance of the various agglomeration factors. 
 
The quantitative exercise involved the computation of spatial concentration indicators 
for the pharmaceuticals industry from the annual Forfás Employment Survey of 
manufacturing operations in Ireland, currently conducted by Forfás (the National 
Policy Advisory Board for Enterprise, Trade, Science, Technology and Innovation). 
The survey is conducted at operations level. An operation in the data set is generally a 
separately incorporated unit of a firm or corporation, corresponding to a set of 
functions on a particular site.4 Individual firms can have several operations in Ireland 
and operations can consist of several plants, producing different products. The 
individual operations were used as a unit of analysis in this paper. The survey 
provides, for each year from 1972 on, data on the location, employment and activity 
of each manufacturing operation in Ireland. Activity is categorised in the survey 
returns using the 4-digit NACE classification.  
 
The definition of the pharmaceutical industry employed in this paper does not 
precisely correspond to the 4-digit NACE codes. The following activities were 
included: drug substances (part of NACE 2441), drug products (NACE 2442), 
diagnostics (part of NACE 2466 and part of NACE 3310) and other intermediate 
chemicals (part of NACE 2441). First inspection of the data set showed that many 
operations were incorrectly coded and substantial recoding was carried out on the 
basis of information obtained through Internet-based research combined with short 
telephone interviews.5 A separate category was included for a small number of 
operations that produced both drug substances and drug products. The final data set 
                                                 
3 As part of a larger research project, a total of 53 staff members were interviewed, including general 
managers, materials managers, personal managers and managers of R&D. The material presented in 
this paper is based mainly on information obtained during the interviews with general managers and 
R&D managers. 
4 There are exceptions. For example, in some cases, the research and development unit of an operation 
is separately incorporated from the manufacturing unit. 
5 For a more detailed report of definitional and recoding issues see [Author, (2006)]. 
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includes a total of 122 pharmaceutical manufacturing operations, 95 of which were in 
operation in 2003 (Table 1).  
 
This data set was used to compute measures of spatial concentration in the 
pharmaceutical industry and its various sub-sectors. The geographic unit of analysis 
used was the administrative county; county boroughs were combined with the 
counties in which they are located, giving a total of 26 observation units.  The level of 
spatial concentration of an industry can be analysed very basically by inspecting the 
geographical distribution of employment across spatial units. The proportion of 
employment in the top region or top two regions can function as a simple measure of 
spatial concentration. A high proportion of employment in the top regions is 
suggestive of the operation of agglomeration economies, although this still needs to 
be demonstrated. This paper presents the geographical distribution of pharmaceutical 
employment across 26 counties. 
 
Many measures of geographical concentration aim to compare the geographic pattern 
of employment or plants for one sector with the pattern of an aggregate (for example, 
all industry). Such measures are often interpreted as an indication of the operation of 
localisation economies. This paper uses the index proposed by Maurel and Sedellot 
(1999) (henceforth referred to as the MS index). The index, γ, controls for differences 
in industrial concentration (distribution of employment over the plants in an industry) 
and provides a measure of spatial concentration of an industry (suggestive of 
localisation economies) beyond what would be expected on the basis of industrial 
concentration. The mathematical derivation of the MS index is shown in Appendix 1. 
Maurel and Sedillot (1999) adopt the following classification of concentration levels: 
a low degree of concentration (γ < 0.02); moderately concentrated (0.02 < γ < 0.05); 
very concentrated  (γ > 0.05).  
 
THE SPATIAL DISTRIBUTION OF THE IRISH PHARMACEUTICAL 
INDUSTRY 
Figure 2 presents the spatial distribution of employment in the pharmaceutical 
industry in Ireland. The overall picture is one of modest concentration. There are two 
main concentrations, one in county Cork county and one in Dublin county. In 2003 
the two counties accounted for 45 per cent of all employment in the industry. Outside 
these two regions there are sizeable secondary concentrations in five other counties. 
Still, a significant number of operations, accounting for 17 per cent of employment, 
are scattered around the country outside these concentrations. The simple figures 
regarding the spatial distribution of pharmaceutical employment are reflected in the 
MS-index, often used as an indication of the operation of localisation economies. The 
value of γ for the total pharmaceutical industry in 2003 was 0.03 - on the low side in 
the ‘moderately concentrated’ category. [Insert figure 2 about here]  
 
A more detailed examination of the industry reveals strongly contrasting spatial 
patterns for the two main sub-sectors. The drug substance or API sub-sector (see 
Figures 3 and 4) is characterised by a large grouping of operations in Cork, a 
secondary grouping in Dublin and a relatively small number of isolated operations 
outside these two counties. County Cork accounts for nearly half of total employment 
while Dublin accounts for another quarter. The MS index for the sub-sector in 2003 is 
0.20, indicating a very high level of spatial concentration. In contrast, drug products 
operations are far less spatially concentrated (see Figures 5 and 6). The largest 
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grouping of drug products operations is in County Dublin, but smaller groupings can 
be found in Mayo, Waterford, and Cork. As regards employment, four counties each 
account for between 13 and 19 per cent of the total. Interestingly, Cork plays only a 
modest role, both in terms of number of plants and employment. The MS index 
computed for the sub-sector in 2003 is -0.02, indicating a very low level of spatial 
concentration. [Insert figures 3, 4, 5 and 6 about here] 
 
Figure 7 shows the trends, over time, for the MS index for all pharmaceutical 
employment and for employment in the drug substance and drug products sub-sectors. 
The drug substance sub-sector has been characterised by a high and rising MS index 
for most of the period since 1972. After a period characterised by a relatively low MS 
index during the 1970s, the sub-sector became ‘very concentrated’ (γ > 0.05) by 1980 
and for the next two decades the index shows a rising trend, reaching the very high 
value of 0.25 in 2001. Since reaching this peak the value has dropped somewhat. In 
contrast, the drug products sub-sector has always been characterised by a low level of 
concentration. The MS index was very low during the early 1970s. From 1975 the 
index rose to a peak in 1984 – but since then has shown a downward trend, falling 
below zero in 1992. [Insert figure 7 about here] 
 
 
THE SPATIAL DYNAMICS OF THE DRUG SUBSTANCE SUB SECTOR: 
CAUSES OF CONCENTRATION AND THE ROLE OF AGGLOMERATION 
ECONOMIES 
The high and rising level of spatial concentration in the drug substance sub-sector 
might suggest the operation of agglomeration economies, and especially localisation 
economies. The remainder of this paper will investigate the determinants of this high 
level of spatial concentration against the background of a more detailed history of 
drug substance plant location in two periods: before and after the mid-1980s. These 
two periods portray significant differences in the location patterns of new plants.  
 
 
The period to the mid-1980s – concentration in Cork Harbour 
Table 2 lists the new drug substance operations established on new sites in the period 
up to 1986. Three drug substance plants were established in the 1960s, all of them in 
the Dublin region.  However, despite this head start, the period of rapid growth of 
drug substance manufacturing activity in Ireland in the 1970s largely bypassed 
Dublin. Until the mid 1970s, in terms of number of operations, the spatial pattern of 
the sub-sector was rather dispersed. Apart from Dublin and the area around Cork City, 
a number of companies had established plants on isolated sites in small rural towns on 
or near the banks of rivers that were used to discharge the wastewater. It was only in 
the second half of the 1970s that Cork really started to establish itself as the centre of 
drug substance production in Ireland. By the mid-1980s there were ten drug substance 
operations in County Cork. The figures do not fully express the dynamics in the area. 
During the period a number of companies expanded their operations via new plants. 
Other companies acquired existing operations or sites (indicated in brackets), often 
significantly expanding the operations in the process. The data on new operations are 
reflected in Figure 8, which charts the changing distribution of employment. Dublin’s 
share of total drug substance employment fell from 54 per cent in 1972 to 14 per cent 
in 1986 while over the same period Cork’s share rose from 36 to 47 per cent. [Insert 
Table 2 about here] [Insert figure 8 about here] 
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The main ‘causes’ (as defined by Marshall) for this spatial concentration in Cork are 
related to government intervention, notably environmental regulation, spatial 
planning, regional policy, and related investment in serviced industrial sites. In the 
early 1970s the IDA identified the pharmaceuticals industry as one of its target 
sectors. Generally, foreign companies were primarily attracted to Ireland because of 
tax incentives and they were relatively easy to persuade to locate where the IDA 
wanted them to locate (O’Farrell, 1975). However, pharmaceutical plants had specific 
locational requirements. Pharmaceutical production facilities - in particular large drug 
substance plants - required sites that were serviced, to a relatively high specification, 
with effluent disposal facilities, fresh water, and electricity. Water is important for 
two reasons. First, drug substance production produced chemically contaminated 
wastewater, which eventually needed to be discharged to surface water. Secondly, the 
production process often required large amounts of fresh water. In general the fresh 
water requirements far outstripped the existing capacities available in most 
municipalities (Leonard, 1988). In fact, one of the early movers, Pfizer in Cork 
Harbour, needed to drill a series of wells to augment the public water supply (Clarke 
et al., 2003). 
  
As part of its strategy, the IDA invested in the necessary infrastructure, concentrating 
most of its limited resources in Cork Harbour, adjacent to Cork City. In the second 
half of the 1970s, the IDA purchased large land banks in the harbour area, notably at 
Little Island and Ringaskiddy. It invested in the required drainage infrastructure, 
including a major marine outfall for discharge of effluent in Ringaskiddy. In addition, 
during the late 1970s/early 1980s, Cork County Council created the largest capacity 
of processed water in the country through the Harbour and City Water Supply 
Scheme. In later years, the Electricity Supply Board installed the required power 
supply (Childs, 1996).  
 
The rapid build-up of suitable physical infrastructure and the availability of sizeable 
industrial sites, often with outline planning permission already in place, made Cork 
Harbour a relatively attractive location for new drug substance projects (Gallagher, 
2003). In addition, having made substantial investments, the IDA was eager to sell the 
land in Cork Harbour. Whenever a company was interested in setting up a drug 
substance plant in Ireland, the IDA would strongly promote its sites in Cork Harbour 
(see also Breathnach, 1982; Meyler and Stobl, 2000). Spatial concentration was 
further driven by the practice of ‘reference selling’ - another element of the IDA’s 
promotion strategy. Potential investors in Ireland were usually invited to visit existing 
flagship companies in their sector. Pfizer in Cork Harbour functioned as the flagship 
company for the pharmaceutical industry. Because of its location it also served to 
specifically promote Cork harbour to potential investors in large-scale processing 
projects.  
 
Thus, in the ten-year period between 1975 and 1986, six of the ten new drug 
substance operations on new sites in Ireland were established in Cork Harbour, and by 
the mid 1980s, the area had firmly established itself as the centre of the 
pharmaceutical industry in Ireland. 
 
The question remains, as to why the IDA concentrated so much of its limited 
resources in Cork Harbour? One of the main reasons was regional planning. During 
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the 1960s and early 1970s, spatial and industrial policy became increasingly 
characterised by an attempt to encourage a shift of manufacturing employment out of 
Dublin, the traditional core area of the national economy. The Buchanan Report 
(Buchanan and Partners, 1968) advocated a policy of concentrated deconcentration in 
a select number of growth centres, notably Cork and Limerick-Shannon.6 The 
industrial policy was to be implemented by the IDA through its regional industrial 
plans. 
 
Partly in response to this, in 1972 the Cork Harbour Commissioners, in close co-
operation with the IDA and Cork planning authorities, proposed the Cork Harbour 
Development Plan, involving a major upgrading of the port, including the 
development of large industrial zones. On Little Island, priority was afforded to a 
range of small and medium-sized enterprises, including pharmaceutical companies. 
Ringaskiddy was to be specifically developed for deep-water industries requiring 
large volumes of water and adequate facilities for large-scale effluent disposal (Brunt, 
1980, 1998 and 2005). 
 
Another reason for concentrating limited resources in Cork Harbour is related to 
environmental regulations and public concerns, although Cork Harbour would not 
have been the only possible location on the basis of this factor. Some physical 
planning and environmental controls on industry had been in place since the 
introduction of the Local Government (Planning and Development) Act in 1963. This 
included the control of wastewater effluent discharged in natural water bodies. 
Although the standards were still relatively relaxed, by the end of the 1960s, local 
governments were already driving quite tough bargains with pharmaceutical plants 
about the level of chemical effluent (Leonard, 1988). For drug substance plants 
located on the banks of inland rivers with limited assimilative capacity7, this created a 
need for intensive on-site treatment of wastewater. This reduced the relative 
attractiveness of such sites, especially in small urban centres with limited municipal 
sewage treatment capacity. On the other hand, it increased the suitability of locations 
near tidal rivers, estuaries or the sea. Large assimilative capacity was one of the most 
important location factors for the first two pharmaceutical companies which located in 
Cork Harbour in the early 1970s (Pfizer and Penn Chemicals). In fact, it is argued that 
Pfizer would probably not have invested in Cork Harbour at all if it had not been 
allowed to discharge untreated wastewater in the Harbour (Leonard, 1988). 
 
In addition, concern among the general public as well as local and central government 
about the potential pollution caused by pharmaceutical and other chemical plants rose 
very quickly during the 1970s (Leonard, 1988). This was partly driven by severe 
odour problems caused by some of the first established drug substance plants. In 
response, between 1970 and 1978, the IDA started to carefully select sites that would 
minimise the environmental impact of new pharmaceutical projects. With respect to 
wastewater discharge, in principle there were many suitable locations in Ireland that 
offered sufficient assimilative capacity. However, intensifying public concern and 
stricter planning regulations made the establishment of isolated large-scale chemical 
synthesis plants in rural settings increasingly difficult. Eli Lilly was the last company 
                                                 
6 Subsequent official policy statements emphasised a greater dispersal of development throughout the 
country (Drudy, 1991) but Cork remained a focus for industrial development. 
7 Assimilative capacity is the capacity of a natural body of water to receive wastewaters or toxic 
materials without deleterious effects. 
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to get planning permission for such a development (at Kinsale in 1978) and, given the 
strong scrutiny by both general public and planning bodies, was fortunate to get it 
(Leonard, 1988). Instead, the aim was to guide plants that produced large amounts of 
effluent into two areas, partly selected because of their great assimilative capacity i.e. 
Cork Harbour and the Shannon Estuary (Leonard, 1988). Initially, in the mid-1970s, 
two new drug substance plants located in the Shannon area. However, with the 
establishment of new, well-serviced, industrial estates in Cork Harbour in the second 
half of the decade, this area became the prime location for new drug substance plants. 
 
It has been suggested that the concentration of drug substance plants in Cork Harbour 
was the result of Cork County Council planning department being particularly 
undemanding of companies where it came to pollution control – the “pollution haven 
hypothesis” (Leonard, 1988). This research found very little support for this idea. In 
fact, Cork County Council was one of the stricter local authorities in Ireland. (See 
Author, 2006), for a more extensive treatment of this issue.) 
 
Let us now consider to what extent the rapid concentration of drug substance plants in 
Cork was driven by the operation of agglomeration economies, and especially 
localisation economies – i.e. a growing number of increasingly specialised input 
suppliers, technological spillovers and a pooled market for workers with specialised 
skills. As regards specialised input suppliers, if this were an important factor in the 
concentration of drug substance plants in Cork, one would expect a co-location of 
buyers and suppliers. Drug substance plants use a range of material inputs, but 
virtually none of these are manufactured in Cork - or Ireland for that matter 
(Company interviews. See also Brennan, 2004). Similarly, none of the interviewed 
drug substance plants sell their output to drug product plants in Ireland. In addition, 
drug products plants are strongly under-represented in Cork. Local specialised input-
output relations can therefore not have been a factor in the concentration of drug 
substance plants in Cork Harbour. 
 
As regards technological spillovers, like most plants operating in Ireland during the 
1970s and 1980s, the drug substance plants had a strong branch-plant character, with 
limited functionality other than bulk manufacturing. Technology was generally 
directly transferred from the strategic plants in the home countries. Headquarter and 
product/process development functions were absent. This makes it unlikely that there 
were any technological externalities embedded in the local milieu, facilitating 
processes of learning and innovation. Such externalities certainly will not have been a 
driver for the further concentration of drug substance plants in Cork Harbour. 
 
Finally, it is unlikely that the concentration process was driven by a market for 
workers with specialised skills in Cork. Most of the pharmaceutical workers in the 
1970s and early 1980s were operatives, with relatively limited skill-levels and 
generally no third-level education. Plants employed a limited amount of engineers and 
chemists, but these needed to be qualified as opposed to specialised. Cork did provide 
a number of more general labour-related advantages. It had an industrial history and a 
number of companies employed engineering skills, notably the Ford Motor factory. In 
addition, Cork had a well-developed third-level education infrastructure, including a 
school of chemistry. Finally, as the second city in Ireland, Cork provided a large pool 
of general labour, much of which was unemployed after significant job-losses in the 
early 1980s (Brunt, 2005). These were undoubtedly important attractions for drug 
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product plants, as they were for a range of other industries. However, along with Cork 
City’s well-developed urban services, these were mostly urbanisation, rather than 
localisation, economies.  
 
It is difficult to determine the precise strength of these urbanisation economies during 
this period. However, they must have been relatively modest since they clearly were 
of insufficient strength to offset the disadvantages of spatial concentration which 
emerged when a number of drug substance plants in Cork Harbour in the late 1970s 
and 1980s (as in other locations in Ireland) were responsible for persistent pollution 
problems, notably air pollution (Leonard, 1988). In an environment of rising public 
concern and protests, some companies preferred to dissociate themselves from these 
problems by locating on isolated sites in more rural locations. At least two companies 
- Elli Lilly in 1978 and Merrell Dow in 1987 - declined to locate in Cork Harbour for 
this reason. Whatever their size, these urbanisation economies cannot, on their own, 
serve as an explanation for the location and concentration of drug substance plants in 
Cork, since similar economies were available in a range of other urban centres. 
 
 
The period since the mid-1980s – shift to Dublin 
The geography of the drug substance sub-sector has changed significantly in the 
period since the mid-1980s. The main change has been the rising significance of 
Dublin as a location for drug substance plants. This change is best captured by the 
location pattern of new drug substance sites since 1987. Table 3 presents the locations 
of sizeable new drug substance operations (employing more than 20 employees) on 
new sites between 1987-2006. With eight new drug substance sites, Dublin accounted 
for half of such sites in Ireland. Although Cork Harbour continued to receive new 
plants on new sites, it was less successful, particularly in the 15-year period from 
1987-2003, when it accounted for only two of the 13 new plants established on new 
sites in Ireland. 
 
[Insert Table 3 about here] 
 
These developments are not fully reflected in the data for investment and employment 
for the drug substances sub-sector. This is because, as in the period before the mid-
1980s, many existing companies made significant repeat investments in Ireland, 
generally expanding on existing sites throughout the country. In addition some newly 
arriving companies purchased existing drug substance sites. As regards the 
distribution of employment, it is only in the early 2000s that we see a significant 
decrease in Cork’s share (from 56 per cent in 2001 to 49 per cent in 2003) and an 
increase in Dublin’s share (from 14 per cent in 2002 to 26 per cent in 2003). The 
reduction in Cork’s share is reflected in a reduction of the MS index (see Figure 7), 
indicating a lower level of spatial concentration in the sub-sector. However, the share 
of the top two counties (Cork and Dublin) actually rose, from 61 per cent in 1986 to 
74 per cent in 2003 (see Figure 8).  
 
The relative shift in drug substances employment from Cork to Dublin was – again - 
strongly influenced by government intervention, notably changing regional planning 
policies and the related location of new well-serviced industrial sites. The 1970s 
policy of industrial dispersal and encouragement of a shift of manufacturing 
employment away from Dublin was progressively relaxed in the 1980s (White, 
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2000a). This was partly a response to the fact that, during the 1970s and 1980s, the 
East Region (containing Dublin) experienced serious industrial decline and its share 
of manufacturing employment shrank significantly (Drudy, 1991). Thus, during the 
1980s and 1990s local authorities, in conjunction with the IDA, developed a number 
of well-serviced industrial estates in County Dublin, along the M50 orbital motorway.  
 
The attraction of such readily-available, large, well-serviced industrial sites has 
increased in the period since the mid-1980s. Increasingly stringent regulations and 
controls are shortening the effective period of patent protection in the pharmaceutical 
industry (Pisano, 1997), making the time it takes to establish a new manufacturing 
plant of strategic importance. In addition, the fermentation processes used in the 
expanding biopharmaceutical sub-sector have very high utility requirements, 
particularly power and wastewater disposal facilities. A good example of 
infrastructure influencing plant location involves the Wyeth Biopharmaceuticals plant 
in Dublin. Initially, the company considered locating this large biopharmaceutical 
facility near its existing drug products plant in Newbridge, a mid-size town some 
50km southwest of Dublin. However, the campus was eventually located in Dublin 
because adequate wastewater treatment services were not immediately available in 
Newbridge (Kildare Nationalist, April 7, 2000). 
 
Thus, since 1987 a new concentration of drug substance plants emerged in Dublin 
while the existing concentration in Cork expanded in absolute terms, particularly 
since 2003. We can again consider the extent to which these concentrations were 
driven by the operation of agglomeration economies, especially localisation 
economies.  
 
As regards specialised input suppliers, the corporate interviews show that, as in the 
previous period, virtually none of the raw materials used by drug substance plants are 
manufactured in Dublin or Cork. The growth of the pharmaceutical industry did help 
to attract a substantial number of process engineering and construction management 
companies to both cities in the 1980s and 1990s (see also Kearny, 2003). Most 
interviewees in Cork and Dublin perceived this concentration of engineering 
companies at their doorstep as beneficial. However, most of these companies service a 
range of other sectors, including other chemical sectors and food processing. 
Therefore, to the extent that the concentration of engineering companies does present 
an advantage, it is largely an urbanisation economy. It is unlikely that it was a very 
important factor in companies’ decisions to locate in Cork or Dublin since 
pharmaceutical plants in more isolated areas do not experience notable disadvantage 
due to distance from the offices of these service firms. Engineering companies tend to 
provide efficient services nationwide. As an interviewee at a more isolated plant 
mentioned: “We have no issue with engineering companies. They are always very 
quick”. In a sense, the advantages operate on the Irish national scale, rather than the 
local scale. 
 
With respect to technological spillovers, although these are difficult to measure, the 
interviews provided little support for the idea that these have played a substantial role 
in the spatial concentration of the drug substance industry since the mid-1980s. This is 
probably partly due to the fact that for a long time the industry remained truncated, 
with virtually no R&D or headquarter functions. It was only at the late-1990s that a 
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number of companies started to add late-stage process development functions to their 
Irish operations.  
 
The interviews provided very little evidence of genuine technological spillovers 
operating via untraded interdependencies and unintentional information exchange and 
facilitating innovation within the local industry. There is a degree of contact between 
local companies and local institutions concerning local infrastructure and production 
climate in general, notably in Cork. However, according to the interviewees this 
contact does not act as medium for technological spillovers facilitating innovation 
within the local industry. Even intentional interaction regarding technology is limited, 
dyadic and often not locally/regionally bounded. The research found very little 
evidence of technological interaction between pharma companies in Ireland, never 
mind between companies in individual clusters. Collaborative research projects 
between companies and local universities have been rare, although there have been a 
handful of examples in recent years. Even then, some of these projects involve 
universities and companies located in different regions. A local IDA representative 
considered the extent of local technological spillovers within the largest spatial 
concentration of plants in Ireland (in Cork) in the following way: 
 
Certainly, from a spatial point of view, it [the drug substance sector in Cork] is a cluster. 
But if you look at the broader definition of a cluster, as defined in terms of the interaction 
between the companies, with the broader environment, a greater level of interaction with 
the community ... I think there is a long way to go yet before you can describe it as a full 
cluster.  
 
Finally, in relation to the relevance of a market for workers with specialised skills, the 
skill-levels in the drug-substance plants have risen sharply compared to the period 
before the mid-1980s. This is partly because of the introduction of more sophisticated 
process technologies. Another reason lies in the expansion or establishment of new 
functions, notably quality control/assurance and process research and development, 
particularly since the end of the 1990s.  As an example, 59 per cent of the staff at a 
recently established drug substance plant have third-level education while 4 per cent 
have a Ph.D. At the process research and development unit of the plant, all staff have 
third-level education and 23 per cent have a Ph.D. Apart from a general rise in skill 
levels, a substantial share of the required skills are also increasingly specialised in the 
particular needs of the drug substance sub-sector.  
 
Interviewees invariably stated that the supply of suitably qualified labour has become 
a very important location factor. To an extent, the existing concentration of drug 
substance plants in Cork and Dublin was perceived as an advantage in this respect, 
but nearly all interviewees related the supply of qualified labour more generally to the 
location of third level institutions and the quality of life in the major urban centres of 
Ireland. In relation to the third level institutions, one IDA executive remarked: “All 
the colleges and universities in the country are supplying the people who work in the 
area. So the pharma sector is a national industry, particularly for the third-level 
institutions. It does not matter which university, your skill is to the same level”. 
Asked which role the local technical skills base had played in its decision to locate in 
Cork Harbour, the manager of a plant established since 1987 replied: “For [our 
company] it was important that we had a university at our doorstep, good technical 
colleges for want of another word, for the supply of qualified staff. (…) So long as 
they have a Regional Technical College it is okay. It does not have to be in Cork”.  
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As mentioned above, most companies now have some interaction with local third-
level institutions regarding course content. It is likely that this interaction has had a 
positive influence on the numbers and specific skills of local graduates. On the other 
hand, the companies have had contact with non-local universities as well and some of 
the companies are represented in national-level forums, influencing the skill levels in 
Ireland as a whole.  
 
As regards quality of life, interviewees noted that qualified and specialised labour is 
very mobile and most companies recruit on a national and international basis (Cf. 
Leibovitz (2004) in relation to the biotechnology industry in Scotland). The targeted 
highly qualified people tend to have relatively high expectations regarding quality of 
life and availability of services, which often translates in a preference for a location in 
or near the major population centres (see also Malecki, 1979). For both reasons 
companies prefer locations in or near these centres. At least two plants that were 
located further away from the main urban centres in Ireland appear to have 
experienced greater difficulties attracting qualified staff and one general manager 
stated that he would not locate in a similar area again for this reason. A number of 
interviewees believed that the attractiveness of Dublin is recently being offset by the 
rising house prices and cost of living in that city. It is believed that this is now having 
a deterring effect on investments in Dublin and may be one of the reasons behind the 
recent resurgence of investment in Cork harbour. 
 
Thus, without completely dismissing the recent emergence of limited localisation 
economies, to the extent that drug substance plants were attracted to Dublin and Cork 
because of the location of third-level institutions and the quality of life that the two 
cities offered as major population centres, the market for qualified and specialised 
workers should again be interpreted mainly as an urbanisation economy. Again, these 
kinds of urbanisation economies were available in other urban centres as well. In this 
respect, other suitable urban centres mentioned during the interviews included 
Galway, Limerick, and Waterford. Thus, although both factors probably confer great 
advantages on Dublin and Cork, it is questionable whether they represent an 
important part of the explanation for the concentration of the sub-sector in these 
particular cities.  
 
As regards the future, interviewees at seven drug substance plants were asked to 
identify the three most important locational considerations if they currently had to 
decide on a location within Ireland. Two factors stood out in the replies. All 
interviewees regarded the availability of skills as an important factor. This factor was 
generally mentioned in conjunction with the proximity to a third-level institute. Five 
interviewees also mentioned the importance of well-serviced sites and utilities. This 
factor was less important for the two other plants because of their relatively small 
scale of operations. Given the fact that there are several urban centres that can satisfy 
the skills requirement, the factor that is likely to most strongly influence the location 
of drug substance plants, and their possible concentration in certain areas, therefore, is 
the availability of well-serviced sites. In support of this contention, a senior manager 
of a recently-established large-scale drug substance plant remarked: 
 
I would say the infrastructural issues are most important because, you know, we have a 
big facility … If you can’t support the facility you have a major problem. Obviously the 
skills base then would be a significant additional factor. (…) With the caveat that you 
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could meet these requirements, mainly the infrastructural ones … there is no reason why 
you could not locate in some of these other centres [other then Dublin and Cork]. But 
again, with the caveat of meeting all of the infrastructural requirements, mainly utilities.  
 
 
Regional planning policies and the concomitant investment in industrial sites and 
infrastructure are therefore likely to play an important role in the future spatial 
distribution of the sub-sector. In this respect the new National Spatial Strategy (NSS) 
2002-2020 (Government of Ireland, 2002) aims to achieve a greater balance of socio-
economic growth between regions, partly through the concentration of development 
in nine national ‘gateway’ centres of critical mass. Under the Strategic Development 
Zone mechanism provided for in the Planning and Development Act 2000, 
streamlined planning processes will apply to locations in, or close to, these gateway 
centres (Government of Ireland, 2000). This mechanism is designed to speed up the 
planning process for specific developments that are of economic importance to the 
State.  
 
The IDA has embraced the NSS (see Dorgan, 2004) and supports it via its FDI 
promotion strategy, including the distribution of ‘strategic sites’ (see also O’Kane, 
2005). These sites are being specifically developed to support large and medium-scale 
manufacturing activities with large utility requirements, especially pharmaceutical 
plants. Apart from Ringaskiddy (in Cork Harbour) and Dublin, the newer strategic 
sites are all located in the vicinity of coastal ‘gateways’: Galway, Dundalk, 
Limerick/Shannon and Waterford (See Figure 9). The IDA has already secured 
advance planning permission for a 400-acre biopharmaceutical campus at the Galway 
strategic site (Beesley, 2006). These developments, if successful, are likely to lead to 
a reduction of the high levels of spatial concentration on a national scale, as measured 
by the MS index. [Insert figure 9 about here] 
 
The findings presented in this paper suggest that, as long as Ireland’s general 
attractiveness to new pharmaceutical projects is retained, the IDA should have 
relatively little difficulty in ‘directing’ companies to well-serviced strategic sites near 
sizeable urban centres other than Dublin and Cork. The problem is that, as of 2005, 
some of the strategic sites outside Cork and Dublin still lacked important elements. 
For example, although plans are in place to construct a new effluent treatment plant to 
serve the strategic site near Waterford, at the time of writing this has still to 
materialise, while the Dundalk site requires an upgrading of its power supply. 
“Ringaskiddy and Grange Castle [in Dublin] are probably the only two places where 
you could walk into tomorrow and say ‘I take that 50 acres there’” (Interview retired 
IDA staff, December 2005). At the same time new strategic sites continue to be 
developed in the existing concentrations (Beesley, 2006).  
 
 
CONCLUSION 
 
 
This paper has shown how, unlike other sub-sectors of the pharmaceutical industry, 
the drug substance sub-sector in Ireland has been spatially concentrated since its 
inception in the early 1960s. During the 1970s and the first half of the 1980s, Cork 
Harbour established itself as by far the single most important centre of drug substance 
production in Ireland. The period since the mid-1980s has been characterised by a 
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relative shift to Dublin, although the drug substance sub-sector in Cork has continued 
to expand. Today, the sub-sector is heavily concentrated in these two locations. 
 
This high level of concentration is sometimes attributed to the operation of 
agglomeration economies, notably Marshal’s triad of localisation economies. This 
paper suggests that the concentration of the drug substance industry in the two 
particular urban centres has largely been driven by government interventions, 
especially environmental and regional planning policy and the related spatially 
selective provision of well-serviced industrial sites and infrastructure. 
 
This is not to say that companies in the two locations do not benefit from 
agglomeration economies. Agglomeration economies have been at play, particularly 
since the mid-1980s. However, they are mainly of the urbanisation type, relating 
particularly to the availability of labour supplies, although limited localisation 
economies have recently been developing in the form of engineering services, tailored 
college courses and the supply of specialised qualified labour. Although urbanisation 
economies have been a factor in the concentration of the industry near two urban 
centres, the fact that these economies have also been available in several other urban 
centres means that they cannot serve as an explanation for the particular concentration 
of the drug substance plants in Cork and Dublin.  
 
The limited role of localisation economies is partly underlined by the development of 
the second concentration of drug substance plants in Dublin since the mid-1980s. 
Under a less restrictive spatial planning regime, the provision of suitable sites and 
utilities in Dublin instigated a substantial shift in the location of new drug substance 
plants.  
 
The evidence presented in this paper does not challenge the large body of work that 
demonstrates the salience of localisation economies, notably technological spillovers, 
in the process of spatial concentration in general. In fact, as mentioned earlier in this 
paper, existing studies suggest that such factors play an important role in the process 
of spatial concentration in the pharmaceutical industry in core economies. Rather, the 
case of the Irish pharmaceutical industry serves to show that, in certain 
sectoral/geographical contexts, government intervention, along with some more 
mundane urbanisation economies, can be the most important driver behind the spatial 
concentration process. Possible areas for generalisation include: other countries where 
governments take a relatively active role in regional planning and the related planning 
of industrial sites; late developing countries with a strong branch-plant character or, at 
least, relatively limited research and development and innovation activity (e.g. Costa 
Rica and Malaysia, Singapore); and industrial sectors characterised by large-scale 
manufacturing plants requiring large and well-serviced industrial sites with high 
utility requirements (e.g. the petrochemical sector).  
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APPENDIX 1 
 
Many measures of geographical concentration aim to compare the geographic pattern 
of employment or plants for one sector with the pattern of an aggregate. Krugman 
(1991) proposed a variant of the Gini coefficient as a measure of spatial concentration 
(suggestive of localisation economies). One of the problems with this measure is that 
it is very sensitive to differences in the size-distribution of the plants. Where 
employment is concentrated in a small number of plants located in a limited number 
of regions, the index always indicates a relatively high level of spatial concentration. 
The index of Maurel and Sedellot (1999) specifically addresses this problem. The 
index controls for differences in industrial concentration (distribution of employment 
over the plants in an industry) and provides a measure of spatial concentration 
(suggestive of localisation economies) beyond what would be expected on the basis of 
industrial concentration. The formula for the index is: 
 
 
The first component in the equation is a measure of raw geographic concentration, 
where: 
  
si is the proportion of sector employment located in geographic area i and xi is the 
proportion of aggregate industrial employment in area i. M denotes the number of 
geographic areas.  
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Control for the size distribution of plants is obtained by adjustment for the Herfindahl 
index8 of industrial concentration (in terms of the distribution of employment across 
plants), where:  
 
zj is the share of plant j in total sector employment and N denotes the number of plants 
in the sector. The result of this adjustment is that a sector will not be regarded as 
spatially concentrated only because its employment is concentrated in a small number 
of plants. 
 
The index is sensitive to the level of sectoral aggregation and the geographic unit of 
analysis applied. Maurel and Sedilot find that an increase in the size of geographic 
unit leads to higher concentration levels while an increase in the level of sectoral 
aggregation (from 4-digit to 2-digit French NAF level) leads to a lower index. Maurel 
and Sedillot used the above classification for an analysis of concentration of industry 
in France at the level of 95 departments and 4-digit NAF. A broadly comparable level 
of aggregation is applied in this paper involving the 26 counties in Ireland and the 4-
digit NACE classification.  
                                                 
8 The Herfindahl index is a measure of industry concentration, generally used as an indicator of 
competition among firms. It is defined as the sum of the squares of the market shares of each individual 
firm. It can range from 0 (a very large amount of small firms) to 1 (a single firm). 
∑
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Table 1: Number of operations and employees in pharmaceutical industry - 2003 
 Foreign Indigenous Total 
 Operations Employees Operations Employees Operations Employees 
Drug substance 30 6379 1 26 31 6405 
Drug product 32 9082 13 886 45 9968 
Both substance 
and product. 5 1772 1 20 6 1792 
Other Interm. 2 109 2 58 4 167 
Diagnostics 5 732 4 411 9 1143 
Total 74 18074 21 1401 95 19475 
Source: Based on Forfás Employment Survey 
 
 
Table 2: Location of new drug substance operations on new sites* - 1972-1986 
First job 
year Company Location 
1961  Loftus Bryan Chemicals (new API operation established by Schering Plough in 1981) Rathdrum, Co. Wicklow 
1964 Squibb Linson (now Bristol-Meyer Squibb)  Dublin 
1967 Hedleys Labs Dublin 
1972 Pfizer Ringaskiddy Cork Harbour 
1972 Chembiotic (New API operation established by Schering-Plough** in 1983) Brinny, Co. Cork 
1972 Klinge Pharma Killorglin, Co. Kerry 
1974 Penn Chemicals (New API operation established by SmithKline in 1976) Cork Harbour 
1974 Merck Sharpe and Dohme Clonmel, Co. Tipperary 
1974 Syntex (now Roche) Clarecastle, Co. Clare 
1975 Galeo (later Pharmacia; now Pfizer Inchera) Cork Harbour 
1977 SIFA (now Schwarz) Shannon, Co. Clare 
1978 Irish Fher (now Cambrex) Cork Harbour 
1979 Plaistow (now Pfizer Little Island) Cork Harbour 
1980 Eli Lilly  Kinsale Co. Cork 
1981 Pilmar (New API operation established by Janssen Pharmaceuticals; now Johnson & Johnson) Cork Harbour 
1981 Newport Synthesis Dublin 
1983 Iropharm (now Honeywell) Arklow, Co. Wicklow 
1985 Angus (New API facility established by Warner Lambert in 1997; now Pfizer) Cork Harbour 
1986 Wexport Pharmaceuticals Cork Harbour 
Note: *New drug substance operations established on existing drug substance sites are indicated in 
brackets. 
**Denotes operation producing both drug substances and drug products 
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Table 3: New drug substance operations with more than 20 employees 
established on new sites - 1987-2006 
First job year Company Location 
1987 Yamanouchi Dublin 
1988 Servier* Arklow, Co. Wicklow 
1989 Kinerton Dublin 
1990 Fort Dodge* Sligo 
1990 Sandoz (now Novartis Ringaskiddy) Cork Harbour 
1992 Helsinn Chemicals Dublin 
1992 Tyco Healthcare Dublin 
1998 Rottapharm* Dublin 
1998 Cascade Biochem Cork Harbour 
2000 Bristol Myers Squibb Dublin 
2000 Wyeth Biopharma Dublin 
2002 Abbott Ireland Pharma Sligo 
2003 Takeda Chemical Dublin 
2003 Recordati Cork Harbour 
2004 Centocor Biologics Cork Harbour 
2006 Amgen Carrigtwohill 
Note: *Denotes both drug substance and formulation plant 
 
 
Figure 1: Employment pharmacuetical sub-sectors - 1972-1993
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Figure 2: Employment pharmaceutical industry by county, 2003 
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Figure 4: Employment in drug substance operations by county, 2003* 
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Figure 3: Location of drug substance operations, 2003 
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Figure 5: Location of drug product operations, 2003 
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 Figure 6: Employment in drug product operations by county, 2003* 
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Figure 7: MS-index pharmaceutical sub-sectors, 1973-2003 
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Figure 8: Share of Cork and Dublin in drug substance employment, 1973-2003 
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Figure 9: Locations of strategic sites, 2006 
 
